• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Improving Regulatory Pathways

The International Alliance of ALS/MND Associations encourages regulatory agencies around the world to develop a framework for global alignment in evaluating potential new therapies for people living with ALS/MND.

The Alliance believes that the ALS/MND community and all stakeholders will benefit from a more cooperative global approach to weighing the risks and benefits of new therapies, especially because drug development and clinical trials take place across many countries. People living with ALS/MND, wherever they live, have an extraordinary unmet need and want the fastest and widest possible access to therapies that may help them. Given how devastating ALS/MND is, this community cannot wait through excessive procedural delays caused by sequential reviews and hand-offs between regulators.

Pivotal (late-stage) clinical trials in ALS/MND are often conducted in several countries, and these global trials are increasingly important for testing the safety and effectiveness of ALS/MND drugs for approval. Drug development may benefit from more uniform global standards of treatment, which can lead to better trial designs.

The Alliance calls for a cooperative, harmonized pathway to approval that makes the evaluation of ALS/MND treatments more effective and faster, guided by the following principles.

Principles

  1. The perspectives, expertise, and experiences of people living with ALS/MND, their caregivers, and their health care providers, including their views on benefits and risks, should be at the core of clinical development and global regulatory review discussions.
  2. Regulators in each country and region align on regulatory review, with the purpose of driving outcomes.
  3. Regulators develop harmonized guidance and process pathways that encourage sponsors to engage with regulators before submitting applications for ALS/MND products, and to submit those applications to participating countries for concurrent review.
  4. Regulators establish ongoing, regular interaction to share information and engage with each other.
  5. The stakeholder community, working with regulators, develops objective measures of progress and uses them in reporting.
  6. Each regulatory authority identifies a Global Regulatory ALS/MND Lead.
  7. A global lead convener role is established, with responsibility that rotates among regulators.
  8. Regulators are transparent with all stakeholders in the ALS/MND community.

Read the full report

These principles were developed at a roundtable on October 5, 2021, that brought together people living with ALS/MND, caregivers, ALS/MND organizations, and industry representatives from more than a dozen countries.

Read the Regulatory Pathways Roundtable Report (PDF, 11 pages) →

Primary Sidebar

Advocacy

  • Advocacy Toolkit

  • Malu Araujo Ribeiro, Brazil

    Malu Araujo Ribeiro, Brazil

  • Frank Bos, Netherlands

    Frank Bos, Netherlands

  • Erwin Coppejans, Belgium

    Erwin Coppejans, Belgium

  • Alex, Argentina

    Alex, Argentina

  • Marco Antonio Alvarez Mercado, Mexico

    Marco Antonio Alvarez Mercado, Mexico

  • Bruno Leanza Mantegna, Italy

    Bruno Leanza Mantegna, Italy

  • Hanne Stenmose, Denmark

    Hanne Stenmose, Denmark

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Lombana, Spain

    Lombana, Spain

  • Rob Tison, USA

    Rob Tison, USA

  • Eddy Lefrancois, Canada

    Eddy Lefrancois, Canada

  • Willi Klein, UK

    Willi Klein, UK

  • Fernando Ocampo Cardona, Colombia

    Fernando Ocampo Cardona, Colombia

  • Carlos Gomez Matallanas, Spain

    Carlos Gomez Matallanas, Spain

  • Rolf Mauch, Switzerland

    Rolf Mauch, Switzerland

  • Paul Launer, USA

    Paul Launer, USA

  • Chen Yin Xue, Taiwan

    Chen Yin Xue, Taiwan

  • Soledad Rodriguez, Spain

    Soledad Rodriguez, Spain

  • Margreth Burger-Saile, Switzerland

    Margreth Burger-Saile, Switzerland

  • Liz Ogg, Scotland

    Liz Ogg, Scotland

  • Claudia Gotti, Brazil

    Claudia Gotti, Brazil

  • Roxana Canova, Argentina

    Roxana Canova, Argentina

  • Dr. Shelly Hoover, USA

    Dr. Shelly Hoover, USA

  • Animesh Kumar, India

    Animesh Kumar, India

  • Ali Var, Turkey

    Ali Var, Turkey

  • Fabrice Kamp, Germany

    Fabrice Kamp, Germany

  • Irene McCaughey, Australia

    Irene McCaughey, Australia

  • Nicholas (Nic) Bowman, South Africa

    Nicholas (Nic) Bowman, South Africa

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Osiel Mendoza, USA

    Osiel Mendoza, USA

  • Antonio Ventriglia, Belgium

    Antonio Ventriglia, Belgium

  • Patrick Shuma, Kenya

    Patrick Shuma, Kenya

  • Lachlan Terry, Australia

    Lachlan Terry, Australia

  • Shay Rishoni, Israel

    Shay Rishoni, Israel

  • Dawn Morton, Scotland

    Dawn Morton, Scotland

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

  • Bob Simonds, USA

    Bob Simonds, USA

  • Glen Victor Peters, Australia

    Glen Victor Peters, Australia

  • Michel Perrozzo, France

    Michel Perrozzo, France

  • Timothy Holman, Switzerland

    Timothy Holman, Switzerland

  • Shay Rishoni, Netherlands

    Shay Rishoni, Netherlands

  • Aida Trzmiel de Guterman, Argentina

    Aida Trzmiel de Guterman, Argentina

  • Philip Brindle, England

    Philip Brindle, England

  • Mauricio Dorin, Argentina

    Mauricio Dorin, Argentina

  • Michael Lee, Australia

    Michael Lee, Australia

  • Kris Van Reusel, Belgium

    Kris Van Reusel, Belgium

  • Amparo Muriel Engativa, Colombia

    Amparo Muriel Engativa, Colombia

  • Joyce Rusinak, USA

    Joyce Rusinak, USA

  • Dorette Lüdi, Switzerland

    Dorette Lüdi, Switzerland

  • Susan Anderson, USA

    Susan Anderson, USA

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login